144 related articles for article (PubMed ID: 38557756)
1. Site-specific Antibody-Nitric Oxide Conjugate HN02 Possesses Improved Antineoplastic and Safety Properties.
Cheng T; Xie J; Yuan X; Guo M; Wu J; Wang M; Huang Z; Zhang J
J Immunother; 2024 Jun; 47(5):149-159. PubMed ID: 38557756
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD24 Antibody-Nitric Oxide Conjugate Selectively and Potently Suppresses Hepatic Carcinoma.
Sun F; Wang Y; Luo X; Ma Z; Xu Y; Zhang X; Lv T; Zhang Y; Wang M; Huang Z; Zhang J
Cancer Res; 2019 Jul; 79(13):3395-3405. PubMed ID: 30918001
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
[TBL] [Abstract][Full Text] [Related]
4. Design and Validation of Linkers for Site-Specific Preparation of Antibody-Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site.
Kumar A; Mao S; Dimasi N; Gao C
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961794
[TBL] [Abstract][Full Text] [Related]
5. N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability.
Ko MJ; Song D; Kim J; Kim JY; Eom J; Sung B; Son YG; Kim YM; Lee SH; You WK; Jung J
MAbs; 2021; 13(1):1914885. PubMed ID: 33904380
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
[TBL] [Abstract][Full Text] [Related]
7. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes.
Drake PM; Albers AE; Baker J; Banas S; Barfield RM; Bhat AS; de Hart GW; Garofalo AW; Holder P; Jones LC; Kudirka R; McFarland J; Zmolek W; Rabuka D
Bioconjug Chem; 2014 Jul; 25(7):1331-41. PubMed ID: 24924618
[TBL] [Abstract][Full Text] [Related]
8. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
[TBL] [Abstract][Full Text] [Related]
9. Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo.
Ma Z; He H; Sun F; Xu Y; Huang X; Ma Y; Zhao H; Wang Y; Wang M; Zhang J
J Cancer Res Clin Oncol; 2017 Oct; 143(10):1929-1940. PubMed ID: 28536738
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the antitumor mechanism of antibody-drug conjugates against tissue factor in stroma-rich allograft models.
Tsumura R; Manabe S; Takashima H; Koga Y; Yasunaga M; Matsumura Y
Cancer Sci; 2019 Oct; 110(10):3296-3305. PubMed ID: 31348600
[TBL] [Abstract][Full Text] [Related]
11. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
Gymnopoulos M; Betancourt O; Blot V; Fujita R; Galvan D; Lieuw V; Nguyen S; Snedden J; Stewart C; Villicana J; Wojciak J; Wong E; Pardo R; Patel N; D'Hooge F; Vijayakrishnan B; Barry C; Hartley JA; Howard PW; Newman R; Coronella J
Mol Oncol; 2020 Jan; 14(1):54-68. PubMed ID: 31736230
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
[TBL] [Abstract][Full Text] [Related]
13. CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110.
Domínguez JM; Pérez-Chacón G; Guillén MJ; Muñoz-Alonso MJ; Somovilla-Crespo B; Cibrián D; Acosta-Iborra B; Adrados M; Muñoz-Calleja C; Cuevas C; Sánchez-Madrid F; Avilés P; Zapata JM
J Hematol Oncol; 2020 Apr; 13(1):32. PubMed ID: 32264921
[TBL] [Abstract][Full Text] [Related]
14. A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells.
Singh R; Setiady YY; Ponte J; Kovtun YV; Lai KC; Hong EE; Fishkin N; Dong L; Jones GE; Coccia JA; Lanieri L; Veale K; Costoplus JA; Skaletskaya A; Gabriel R; Salomon P; Wu R; Qiu Q; Erickson HK; Lambert JM; Chari RV; Widdison WC
Mol Cancer Ther; 2016 Jun; 15(6):1311-20. PubMed ID: 27197308
[TBL] [Abstract][Full Text] [Related]
15. A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer.
Huhe M; Lou J; Zhu Y; Zhao Y; Shi Y; Wang B; Sun X; Zhang X; Zhang Y; Chen ZN
Biochem Biophys Res Commun; 2019 Jun; 513(4):1083-1091. PubMed ID: 31010682
[TBL] [Abstract][Full Text] [Related]
16. Advances in the Development of Site-Specific Antibody-Drug Conjugation.
Zhou Q; Kim J
Anticancer Agents Med Chem; 2015; 15(7):828-36. PubMed ID: 25731178
[TBL] [Abstract][Full Text] [Related]
17. Novel Thienoduocarmycin-Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies.
Valsasina B; Orsini P; Caruso M; Albanese C; Ciavolella A; Cucchi U; Fraietta I; Melillo N; Fiorentini F; Rizzi S; Salsa M; Isacchi A; Gasparri F
Mol Cancer Ther; 2023 Dec; 22(12):1465-1478. PubMed ID: 37722716
[TBL] [Abstract][Full Text] [Related]
18. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
[TBL] [Abstract][Full Text] [Related]
19. SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models.
Yang CY; Wang L; Sun X; Tang M; Quan HT; Zhang LS; Lou LG; Gou SH
Acta Pharmacol Sin; 2019 Jul; 40(7):971-979. PubMed ID: 30643210
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
